Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201420152016201720182019
Sales115153230234246271
EBITDA33,656,5118110113145
Operating profit (EBIT)32,555,910737,694,5116
Pre-Tax Profit (EBT)------
Net income13,133,418,5-40,053,076,4
P/E ratio49,223,732,3-4,5613,58,76
EPS ( $ )0,290,730,42-2,250,761,17
Dividend per Share ( $ )------
Yield------
Reference price ( $ )14.2817.2913.5510.2510.2510.25
Announcement Date03/04/2015
11:30am
03/08/2016
11:30am
03/08/2017
11:31am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201420152016201720182019
Debt-14492,224313813,5
Finance45,8-----
Operating income (EBITDA)33,656,5118110113145
Leverage
(Debt/EBITDA)
-2,55x0,78x2,22x1,23x0,09x
Capital Expenditure0,073,561,231,071,061,19
Book Value Per Share (BVPS)1,85 $1,90 $3,85 $1,07 $2,86 $5,19 $
Cash Flow per Share0,69 $0,41 $0,19 $1,35 $1,53 $2,09 $
Announcement Date03/04/2015
11:30am
03/08/2016
11:30am
03/08/2017
11:31am
---
Balance Sheet Analysis
Assessed data source :
© 2017 Thomson Reuters
Financial Ratios

Size 2017e 2018e
Capitalization 477 M$ -
Entreprise Value (EV) 721 M$ 615 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS) 13,5x
Capitalization / Revenue 2,03x 1,94x
EV / Revenue 3,07x 2,50x
EV / EBITDA 6,57x 5,46x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 9,58x 3,58x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) 16,1% 38,4%
operating Leverage (Delta EBIT / Delta Sales) - 31,0x
Net Margin (Net Profit / Revenue) -17,1% 21,5%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) 62,2% 78,2%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   0,45% 0,43%
Cash Flow / Sales 26,7% 29,0%
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 2,22x 1,23x
EPS & Dividend